Related Experiment Video

Updated: May 1, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.9K

Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era

Alberto Dominguez-Rodriguez1, Pedro Abreu-Gonzalez1, Russel J Reiter1

  • 1Alberto Dominguez-Rodriguez, Department of Cardiology, Complejo Hospitalario Universitario de Canarias, 38320 Tenerife, Spain.

World Journal of Cardiology
|March 27, 2014
PubMed

Insights

Primary percutaneous coronary intervention restores blood flow after heart attacks but causes reperfusion injury. Several pharmacological therapies show promise in reducing this damage and improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Science

Background:

  • ST-segment elevation myocardial infarction requires timely reperfusion therapy.
  • Primary percutaneous coronary intervention is the standard treatment for myocardial infarction.
  • Reperfusion injury is a significant complication following restoration of blood flow.

Purpose of the Study:

  • To review the pathophysiology of myocardial reperfusion injury.
  • To highlight promising pharmacological interventions for reducing reperfusion injury.
  • To discuss future strategies for improving clinical outcomes in coronary heart disease patients.

Main Methods:

  • Literature review of pathophysiological mechanisms of reperfusion injury.
  • Identification and summary of pharmacological agents studied for myocardial reperfusion injury.
  • Analysis of clinical studies demonstrating the efficacy of these agents.

Main Results:

  • Reperfusion injury causes additional myocardial damage after blood flow restoration.
  • Several pharmacological agents, including cyclosporin-A and exenatide, show potential in preclinical and early clinical studies.
  • These therapies aim to mitigate infarct size and preserve cardiac function.

Conclusions:

  • Pharmacological interventions offer a promising future for preventing reperfusion injury.
  • Targeting reperfusion injury can improve clinical outcomes in patients with myocardial infarction.
  • Further research and clinical trials are needed to validate these therapeutic strategies.

Keywords:
Adjunctive therapyCardioprotectionInfarct sizeMyocardial reperfusion injuryST-elevation myocardial infarction

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

2.7K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493